featured
Neoadjuvant Relatlimab and Nivolumab for Resectable Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Nature
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Nature 2022 Nov 01;611(7934)155-160, RN Amaria, M Postow, EM Burton, MT Tezlaff, MI Ross, C Torres-Cabala, IC Glitza, F Duan, DR Milton, K Busam, L Simpson, JL McQuade, MK Wong, JE Gershenwald, JE Lee, RP Goepfert, EZ Keung, SB Fisher, A Betof-Warner, AN Shoushtari, M Callahan, D Coit, EK Bartlett, D Bello, P Momtaz, C Nicholas, A Gu, X Zhang, BR Korivi, M Patnana, SP Patel, A Diab, A Lucci, VG Prieto, MA Davies, JP Allison, P Sharma, JA Wargo, C Ariyan, HA TawbiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.